acceleronpharma.com
Acceleron Pharma » Dalantercept
http://www.acceleronpharma.com/products/dalantercept
POSTERS, PRESENTATIONS & PUBLICATIONS. The DART Study Part 1: Updated Results of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. International Kidney Cancer Symposium. The DART Study Part 2: A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients. For Advanced / Metastatic Cancer. Dalantercept (ACE-041) is an investigational protein therapeutic that inhibits angiogenesis by preventing BMP9 and BMP10, proteins in the TGF-β superfami...